|
|
Article: US FDA grants marketing approval of Actonel for prevention and treatment of osteoporosis; New osteoporosis therapy proven to consistently reduce vertebral fracture risk in just one year.
- Article from:
- M2 Presswire
- Article date:
- April 18, 2000
CopyrightCOPYRIGHT 2000 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-18 April 2000-US FDA: US FDA grants marketing approval of Actonel for prevention and treatment of osteoporosis; New osteoporosis therapy proven to consistently reduce vertebral fracture risk in just one year (C)1994-2000 M2 COMMUNICATIONS LTD
RDATE:17042000
Cincinnati, OH, and Parsippany, NJ -- Procter & Gamble (NYSE: PG) and Aventis Pharmaceuticals, the U.S. pharmaceutical business of Aventis S.A. (NYSE: AVE), announced today that the U.S. Food and Drug Administration (FDA) approved 5 mg Actonel (risedronate sodium tablets) for the treatment and prevention of postmenopausal osteoporosis (PMO) and glucocorticoid-induced osteoporosis ...